Athenex Reports Positive Early Signals of Clinical Trial of Tirbanibulin With Psoriasis Patients

Athenex (ATNX) and biopharmaceutical company PharmaEssentia Corp. (TWSE:6446) on Thursday outlined positive early signals in patients with psoriasis who were treated with KX2-391 (INN:tirbanibulin) 1% ointment once a day for five days in a phase 1 clinical trial. The study involved six patients with mild to moderate psoriasis. All patients showed some improvement after the treatment, the companies said. The […]